Ulipristal for Endometriosis-related Pelvic Pain

Endometriosis Clinical Trial

Official title:

Phase IV Pilot Study of Ulipristal Acetate for Treatment of Endometriosis-related Pelvic Pain

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02213081
• Other study ID #: STU00091840
• Status: Completed
• Phase: Phase 4
• Start date: February 2015
• Est. completion date: December 2016

Study information

• Verified date: May 2024
• Source: Northwestern University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this research is to assess the benefit of a medication (ulipristal) for alleviation of symptoms in women with chronic, endometriosis-related pelvic pain.

Description:

This study will assess the use of a medication to improve symptoms of chronic, endometriosis-related pelvic pain among women who did no achieve relief with prior surgical and medical treatments.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1
• Est. completion date: December 2016
• Est. primary completion date: November 2016
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Diagnosis of endometriosis with surgical confirmation via laparoscopy performed within 3 years prior to study enrollment
• English-speaking reproductive-age women (18-50yo) with regular, cyclical menses
• Treatment-refractory endometriosis, as defined by persistent or recurrent pelvic pain following one or more treatments involving surgery and/or hormonal treatment
• Dysmenorrhea and chronic pelvic pain for a least one week out of the month during past 5 months or longer
• Endometrial biopsy before and after intervention
• Adequate organ and marrow function as defined below:
• leukocytes = 3,000/microliter
• absolute neutrophil count = 1,500/microliter
• platelets = 100,000/microliter
• total bilirubin within normal institutional limits
• Liver function tests = 2.5 X institutional upper limit of normal
• creatinine within normal institutional limits
• Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
• A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the

following criteria:

• Has not undergone a hysterectomy or bilateral oophorectomy; or
• Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
• Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

• Undiagnosed vaginal bleeding
• Abnormal results from endometrial biopsy
• Presence of ovarian cysts = 3 cm
• Pregnancy
• Refusal to adhere the birth control strategy of the study (use of a combination of a condom and a vaginal sponge during each intercourse while on ulipristal, plus one month before the onset and one month after the completion of ulipristal therapy)
• Women taking digoxin, dabigatran or etexilate due to interference of ulipristal acetate with the concentration of these substances bound by plasma proteins.
• Women taking moderate to potent inducers of hepatic metabolism (e.g. erythromycin, ketoconazole, ritonavir, nefazodone).
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to Ulipristal.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active pulmonary, cardiac, renal, hepatic or thromboembolic disease, infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Related Conditions & MeSH terms

• Endometriosis
• Pelvic Pain

Intervention

Drug:
• Ulipristal
Patient will take 15mg every other day, or every 4 days per week.

Locations

Country	Name	City	State
United States	Northwestern University, Prentice Women's Hospital	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
Northwestern University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Pain With Bowel Movements	Patient will document self-reported weekly average pelvic pain scores with defecation (0 to 10 where 0 is no pain and 10 is worst pain) for one month prior to starting treatment, while receiving treatment for 3 months and for one full month subsequent to treatment.	Patient will document self-reported daily pain scores via visual analogue scale(0 to 10 where 0 is no pain and 10 is worst pain) for one month prior to starting treatment (1 month),while receiving treatment (3 months)after cessation of treatment(1 month)
Primary	Pelvic Pain	Scores were collected daily and averaged together for each period	Patients will document self-reported daily pain scores via visual analogue scale(0 to10 where 0 is no pain and 10 is worst pain)for one month prior to starting treatment (1 month),while receiving treatment (3 months) after cessation of treatment (1 month)
Secondary	Vaginal Bleeding	Patient will record the # of tampons or pads they use each week while enrolled in the study (1 month pre-medication, 3 months during medication, 1 month after medication).	5 months
Secondary	Pain With Sexual Intercourse	If sexually active, patients will document self-reported weekly average pelvic pain scores (0 to 10 where 0 is no pain and 10 is worst pain) with sexual intercourse for one month prior to starting treatment, while receiving treatment for 3 months and for one full month subsequent to treatment.	5 months